With the knowledge we have today, SP100 and SP140 can be considered potential candidates for further exploration in precision oncology, especially for complex malignancies where chromatin remodeling and immune evasion may lead to therapeutic resistance, such as clear cell renal cell carcinoma (ccRCC) and gastric cancer. The gene discussed is SP100; the disease is nonpapillary renal cell carcinoma.